Piper Sandler lowered the firm’s price target on Immunome (IMNM) to $21 from $23 and keeps an Overweight rating on the shares after the ...

Issued on behalf of Oncolytics Biotech Inc. "With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep's potential in HR+/HER2- metastatic breast cancer,” said ...

Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls.

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Springworks Therapeutics (SWTX ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

Encouraging results from Phase 1/2 study of mirdametinib in pediatric patients with low-grade glioma also to be presented in oral session at SNO – STAMFORD, Conn., (GLOBE NEWSWIRE) -- SpringWorks ...

Nov. 12, 2024 — Researchers have found that the way DNA is packaged in cells can directly impact how fast DNA itself is copied during cell division. They discovered that DNA packaging sends ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

OGSIVEO ® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company's first FDA-approved therapy.